Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper
暂无分享,去创建一个
Jane R Kenny | Eugenia Kraynov | Lei Zhang | Leslie J Dickmann | R. Evers | Lei Zhang | J. G. Slatter | Aarti H Patel | E. Kraynov | S. Dallas | J. Kenny | J Greg Slatter | Raymond Evers | O. Fahmi | L. Dickmann | Shannon Dallas | Odette A Fahmi | Theresa Nguyen | Theresa V. Nguyen | Aarti H. Patel | J. Greg Slatter | Jane R. Kenny | Leslie J Dickmann | Aarti H. Patel
[1] L. Wienkers,et al. Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression. , 2012, Biochemical pharmacology.
[2] E. Benedetti,et al. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. , 2002, Transplantation proceedings.
[3] S. Dallas,et al. Drug Interaction Assessment Strategies: Small Molecules versus Therapeutic Proteins , 2013 .
[4] G. Fricker,et al. Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-α and Lipopolysaccharide , 2006, Molecular Pharmacology.
[5] Saileta Prabhu,et al. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? , 2012, Expert opinion on drug metabolism & toxicology.
[6] F. Jamali,et al. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. , 2009, Basic & clinical pharmacology & toxicology.
[7] L. Corcos,et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. , 1993, Molecular pharmacology.
[8] Hayley S. Brown,et al. Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.
[9] K. Akakura. [Inflammatory cytokines]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[10] P. Maurel,et al. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture , 1995, Hepatology.
[11] Jing-Hung Wang,et al. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] O. Fardel,et al. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines , 2009, Expert opinion on drug metabolism & toxicology.
[13] R. Witkamp,et al. Direct cell-to-cell contact between Kupffer cells and hepatocytes augments endotoxin-induced hepatic injury. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[14] B. Blumberg,et al. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism , 2009, Nuclear receptor signaling.
[15] R. Evers,et al. Utility of In Vitro Methods in Drug–Drug Interaction Assessment and Prediction for Therapeutic Biologics , 2013 .
[16] A. Kashuba,et al. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[17] Mehmet Toner,et al. A Stable Long‐Term Hepatocyte Culture System for Studies of Physiologic Processes: Cytokine Stimulation of the Acute Phase Response in Rat and Human Hepatocytes , 1992, Biotechnology progress.
[18] L. Wienkers,et al. Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture , 2011, Drug Metabolism and Disposition.
[19] Olivier Fardel,et al. Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-α or Interleukin-6 , 2009, Drug Metabolism and Disposition.
[20] A. El-Kadi,et al. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. , 2009, Current drug metabolism.
[21] Steven W. Martin,et al. AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development , 2011, The AAPS Journal.
[22] Y. Lai,et al. Regulation of MRP2/ABCC2 and BSEP/ABCB11 Expression in Sandwich Cultured Human and Rat Hepatocytes Exposed to Inflammatory Cytokines TNF-α, IL-6, and IL-1β , 2010, The Journal of Biological Chemistry.
[23] O. Fardel,et al. Regulation of drug transporter expression by oncostatin M in human hepatocytes. , 2011, Biochemical pharmacology.
[24] J. Halpert,et al. Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. , 2001, Molecular pharmacology.
[25] M. Moya,et al. Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. , 2009, Current drug metabolism.
[26] Steven W. Martin,et al. How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential , 2011, Drug Metabolism and Disposition.
[27] A. El-Kadi,et al. Role of NF-κB in the regulation of cytochrome P450 enzymes , 2009 .
[28] A. D. Rodrigues,et al. Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[29] Edward T. Morgan,et al. Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes , 2007, Drug Metabolism and Disposition.
[30] L. Pape,et al. Interleukin-2 receptor antibodyinduced alterations of ciclosporin dose requirements in paediatric transplant recipients , 2000, The Lancet.
[31] B. Kuhn,et al. Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis , 2011, Clinical pharmacology and therapeutics.
[32] S. Karpen,et al. Endotoxin leads to rapid subcellular re-localization of hepatic RXRα: A novel mechanism for reduced hepatic gene expression in inflammation , 2004, Nuclear receptor.
[33] D. Brocks,et al. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[34] P. Cheng,et al. Mechanisms of cytochrome P450 regulation by inflammatory mediators. , 2002, Toxicology.
[35] Qiang Zhang. Regulation of drug transporters , 2012 .
[36] Wen Xie,et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. , 2006, The Journal of biological chemistry.
[37] L. Wienkers,et al. Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. , 2012, Current drug metabolism.
[38] M. T. Donato,et al. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes. , 1997, The Journal of pharmacology and experimental therapeutics.
[39] M. Piquette-Miller,et al. IMPACT OF ENDOTOXIN-INDUCED CHANGES IN P-GLYCOPROTEIN EXPRESSION ON DISPOSITION OF DOXORUBICIN IN MICE , 2005, Drug Metabolism and Disposition.
[40] E. Morgan. Regulation of cytochrome p450 by inflammatory mediators: why and how? , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[41] J. Castell,et al. Inhibition of monooxygenase activities in human hepatocytes by interferons. , 1993, Toxicology in vitro : an international journal published in association with BIBRA.
[42] E. Vasquez,et al. OKT3 therapy increases cyclosporine blood levels. , 1997, Clinical transplantation.
[43] J. Castell,et al. Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. , 1998, The Journal of pharmacology and experimental therapeutics.
[44] Honghui Zhou,et al. De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes. , 2012, Current drug metabolism.
[45] A. Kivitz,et al. Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. , 2012, International journal of clinical pharmacology and therapeutics.
[46] ET Morgan,et al. Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics , 2009, Clinical pharmacology and therapeutics.
[47] S. Dallas,et al. Interleukins-12 and -23 Do Not Alter Expression or Activity of Multiple Cytochrome P450 Enzymes in Cryopreserved Human Hepatocytes , 2013, Drug Metabolism and Disposition.
[48] Shiew-Mei Huang,et al. CYP-Mediated Therapeutic Protein-Drug Interactions , 2010, Clinical pharmacokinetics.
[49] L. Wienkers,et al. Drug Interactions of Cytokines and Anticytokine Therapeutic Proteins , 2013 .
[50] Micheline Piquette-Miller,et al. Regulation of drug transporters during infection and inflammation. , 2007, Molecular interventions.
[51] F. Jamali,et al. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[52] Myung G. Lee,et al. Effects of endotoxin derived from Escherichia coli lipopolysaccharide on the pharmacokinetics of drugs , 2008, Archives of pharmacal research.
[53] I. Mahmood,et al. Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies , 2007, Journal of clinical pharmacology.
[54] Shiew-Mei Huang,et al. Scientific Perspectives on Therapeutic Protein Drug–Drug Interaction Assessments , 2013 .
[55] M. Jamei,et al. A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL‐6 , 2013, Clinical pharmacology and therapeutics.
[56] S. Shioda,et al. Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. , 2007, European journal of pharmacology.
[57] L Zhang,et al. Therapeutic Protein–Drug Interactions and Implications for Drug Development , 2010, Clinical pharmacology and therapeutics.
[58] J. Pascussi,et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. , 2000, Biochemical and biophysical research communications.
[59] J. Pohl,et al. Dual Mechanisms of CYP3A Protein Regulation by Proinflammatory Cytokine Stimulation in Primary Hepatocyte Cultures , 2009, Drug Metabolism and Disposition.
[60] K. Seitz,et al. Pharmacokinetic Drug‐Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check , 2007, Journal of clinical pharmacology.
[61] Justin C. Earp,et al. Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop , 2013, The AAPS Journal.
[62] C. Galanos,et al. Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats. , 1982, British journal of experimental pathology.
[63] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[64] Honghui Zhou,et al. Mechanisms of monoclonal antibody-drug interactions. , 2011, Annual review of pharmacology and toxicology.
[65] T. Nishioku,et al. Lipopolysaccharide-activated microglia lower P-glycoprotein function in brain microvascular endothelial cells , 2012, Neuroscience Letters.
[66] F. Theil,et al. Highlights From a Recent BIO Survey on Therapeutic Protein‐Drug Interactions , 2012, Journal of clinical pharmacology.
[67] T. A. Richardson,et al. Regulation of drug-metabolizing enzymes and transporters in inflammation. , 2006, Annual review of pharmacology and toxicology.